Accord Agrees Leuprolide Deal as Part of Differentiation Strategy

13 Mar 2019

• By Aidan Fry

Accord is furthering its push into added-value medicines by entering into a licensing agreement for Foresee’s injectable suspension leuprolide injectable.

Darts — A global alliance with Foresee for ready-to-use formulation of leuprolide forms part of Accord Healthcare's differentiation strategy • Source: Shutterstock

Accord Healthcare has struck an exclusive global licensing deal for the FP-001 leuprolide mesylate injectable suspension (LMIS) being developed by Taiwan’s Foresee Pharmaceuticals. The global deal for the subcutaneous delayed-release formulations excludes the US, Japan, mainland China, Taiwan and territories for which Foresee had already struck partnering deals for FP-001, primarily in the Middle East and North Africa (MENA) region.

In return for commercial rights in regions including Europe and several emerging markets, Accord will give its partner up to...